Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.26 USD

2.26
2,221,224

+0.24 (11.88%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $2.24 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.19%
3Hold10.25%
4Sell5.78%
5Strong Sell3.18%
S&P50011.60%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (154 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses

by Zacks Equity Research

FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.

Zacks Equity Research

Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?